GAMMA Investing’s Emergent Biosolutions EBS Stock Holding History

GAMMA Investing’s Portfolio EBS Stock Details EBS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$5.2K	Buy	620 +197	+47%	+$1.65K	﹤0.01%	3449
2026 Q1	$3.51K	Buy	423 +64	+18%	+$663	﹤0.01%	3498
2025 Q4	$4.44K	Buy	359 +72	+25%	+$771	﹤0.01%	3335
2025 Q3	$2.53K	Sell	287 -109	-28%	-$848	﹤0.01%	3389
2025 Q2	$2.53K	Sell	396 -190	-32%	-$1.09K	﹤0.01%	3338
2025 Q1	$2.85K	Sell	586 -1,028	-64%	-$8.51K	﹤0.01%	3298
2024 Q4	$15.4K	Sell	1,614 -96	-6%	-$881	﹤0.01%	2397
2024 Q3	$14.3K	Buy	1,710 +968	+130%	+$8.8K	﹤0.01%	2295
2024 Q2	$5.06K	Buy	+742	New	+$3.19K	﹤0.01%	2573

Other funds holding EBS

YIH

Y-Intercept (HK) Hong Kong $5.05B AUM 17.89% 1-Year Est. Return

Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return

Wealth Enhancement Advisory Services Plymouth, Minnesota $59.8B AUM 29.42% 1-Year Est. Return

Diversified Trust Memphis, Tennessee $6.24B AUM 28.78% 1-Year Est. Return

BWM

Baron Wealth Management Troy, Michigan $386M AUM 30.18% 1-Year Est. Return

Herold Advisors New York $506M AUM 26.75% 1-Year Est. Return

FFA

Farther Finance Advisors San Francisco, California $12.8B AUM 26.53% 1-Year Est. Return

MFT

Moisand Fitzgerald Tamayo Orlando, Florida $1.02B AUM 21.26% 1-Year Est. Return

TCM

Triumph Capital Management Denver, Colorado $552M AUM 20.75% 1-Year Est. Return

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

GAMMA Investing's EBS Position: Q2 2026 in Review

GAMMA Investing increased its Emergent Biosolutions (EBS) stake by 47% in Q2 2026, buying an estimated $1.65K and bringing the position to 620 shares worth $5.2K. The position accounts for ﹤0.01% of the portfolio, ranked #3449.

GAMMA Investing first reported a position in EBS in Q2 2024 and has held it in 9 quarters since. The position peaked at $15.4K in Q4 2024. 20 funds tracked by Wall St. Rank hold EBS as of Q2 2026.

GAMMA Investing held 620 shares of Emergent Biosolutions worth $5.2K as of Q2 2026.
GAMMA Investing bought 197 Emergent Biosolutions shares in Q2 2026, an estimated $1.65K.
Emergent Biosolutions made up ﹤0.01% of GAMMA Investing's portfolio in Q2 2026, its #3449 holding.
GAMMA Investing first reported a position in Emergent Biosolutions in Q2 2024 and has held it in 9 quarters since.
GAMMA Investing's Emergent Biosolutions position peaked at $15.4K in Q4 2024.
20 funds tracked by Wall St. Rank held Emergent Biosolutions as of Q2 2026.

Based on GAMMA Investing's 13F filing for Q2 2026, filed 7 Jul 2026.